Breaking News
0

Seattle Genetics Halts Phase III Study On Leukemia Drug

By Zacks Investment ResearchJun 19, 2017 10:31PM ET
www.investing.com/analysis/seattle-genetics-halts-phase-iii-study-on-leukemia-drug-200196333
Seattle Genetics Halts Phase III Study On Leukemia Drug
By Zacks Investment Research   |  Jun 19, 2017 10:31PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Seattle Genetics, Inc. (NASDAQ:SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients. The company took this decision after consulting the Independent Data Monitoring Committee (IDMC) and after the review of data on Jun 16, 2017.

The data demonstrated higher number of deaths including fatal infections in vadastuximab talirine-containing arm versus control arm of trial. The company stated the safety concern in the trial did not appear related to hepatotoxicity. The company is discontinuing the patient enrollment and treatment in all of its vadastuximab talirine clinical trials. The company will closely review data and consult with FDA to determine future plans for vadastuximab talirine development program.

The shares of the company fell about 4% following the news. Seattle Genetics outperformed the Zacks classified Medical-Biomedical/Genetics industry year to date. The stock jumped almost 17.3% while the industry gained 6.4%.

Earlier in Dec 2016, the FDA had placed a partial clinical hold on two phase I trials to evaluate the potential risk of liver toxicity in patients treated with vadastuximab talirine of vadastuximab talirine in acute myeloid leukemia (AML). The clinical hold was initiated to evaluate a potential risk on patients who underwent a stem cell transplant either before or after the treatment. However, the FDA lifted the clinical hold in Mar 2017. The clinical hold on vadastuximab talirine was resolved through an analysis of the clinical data from over 300 patients treated to date and evaluated by an independent committee of clinical experts, collaborative interactions with the FDA and protocol amendments designed to further enhance patient safety.

The discontinuation of the trial is a key pipeline setback for the company. Consequently, the company will focus on other pipeline candidates. The company remains on track to release data from the Adcetris’ phase III ECHELON-1 trial in frontline Hodgkin lymphoma, and to advance enfortumab vedotin into a pivotal trial in metastatic urothelial cancer in the second half of 2017 under its collaboration with Astellas Pharma Inc. (OTC:ALPMY) .

Zacks Rank & Stocks to Consider

Seattle Genetics currently carries a Zacks Rank#3 (Hold). Better-ranked stocks in health care sector include VIVUS, Inc. (NASDAQ:VVUS) and MEI Pharma, Inc. (NASDAQ:MEIP) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company delivered positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company has increased 0.9% year to date.

MEI Pharma’s estimates moved up from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company came up with positive earnings surprises in three of the four trailing quarters, with average beat of 66.56%. The share price of the company has increased 43% year to date.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>



VIVUS, Inc. (VVUS): Free Stock Analysis Report

Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report

MEI Pharma, Inc. (MEIP): Free Stock Analysis Report

Original post
Seattle Genetics Halts Phase III Study On Leukemia Drug
 
Seattle Genetics Halts Phase III Study On Leukemia Drug

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email